• Channels
    • All News
    • Premium Content
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

Da­ta do not sup­port wide­spread Covid vac­cine boost­ers right now, out­go­ing FDA lead­ers write in the Lancet

Last year
FDA+
Coronavirus

Ab­b­Vie dives deep­er in­to eye care, pay­ing $370M cash — with a $1.4B sweet­en­er — to part­ner on VEGF gene ther­a­py

Last year
Deals

Sanofi places new $1.9B bet even as its last sours; Sam Wak­sal's new biotech ideas; Cell ther­a­py time for Roche; and more

Last year
Weekly

Boehringer In­gel­heim taps a pop­u­lar an­ti­body dis­cov­ery play­er for ac­cess to drug 'li­brary of li­braries'

Last year
Deals

In a first, FDA warns a re­searcher for fail­ing to sub­mit da­ta 3 years af­ter tri­al com­ple­tion

Last year
FDA+

Af­ter decade-plus of fail­ures, As­traZeneca fi­nal­ly gets a win for sto­ried im­munother­a­py (kind of)

Last year
R&D

Bio­gen CEO Vounatsos laments 'con­fu­sion' and 'mis­in­for­ma­tion' lead­ing to chal­lenges with Aduhelm up­take

Last year
Pharma

Ther­mo Fish­er, as part of glob­al ex­pan­sion plans, out­lines new sin­gle-use site in Nashville

Last year
Manufacturing

Jen­nifer Doud­na's di­ag­nos­tic spin­out rais­es Mam­moth round as it ex­pands to ther­a­pies

Last year
Financing
Cell/Gene Tx

Medicx­i's mega-start­up Centes­sa rolls out first da­ta for he­mo­phil­ia drug with plans to charge ahead in­to piv­otal test

Last year
R&D

The Tachi Ya­ma­da lega­cy tree con­tin­ues to grow with a new gene edit­ing biotech from Jim Wil­son

Last year
Financing
Startups

A top pick in Paul Hud­son's cam­paign to re­vive the pipeline at Sanofi blows up in PhI­II

Last year
R&D

Top bio­phar­ma ex­ecs of­fer scare tac­tics and mixed mes­sages on drug pric­ing bills mak­ing their way to Capi­tol Hill

Last year
R&D
Pharma

One of Tachi's new­ly born lega­cy biotechs rais­es $135M and en­lists an A-list board to ad­vance late-stage vac­cine

Last year
Financing

Sanofi picks up Kad­mon and its trans­plant drug in $1.9B buy­out, giv­ing Sam Wak­sal 2 Big Phar­ma buy­outs un­der his belt

Last year
Deals

Macro­Gen­ics flips over an OS dud for can­cer drug Mar­gen­za in sur­pris­ing turn­around from ear­li­er da­ta

Last year
R&D

UK unions lam­bast plan for ma­jor lay­offs at MHRA as Brex­it takes its toll

Last year
People
Pharma

Mov­ing on from a ma­jor set­back, Roche lines up a new Hunt­ing­ton's pro­gram for gene ther­a­py sub Spark

Last year
Deals
R&D

Can­cer gi­ant Roche splash­es in­to cell ther­a­py with $3B+ Adap­ti­m­mune deal for off-the-shelf drugs

Last year
Deals
Cell/Gene Tx

Liv­er tu­mors in an­i­mals trig­ger clin­i­cal hold for Bio­Marin gene ther­a­py — high­light­ing a re­cur­ring con­cern

Last year
Cell/Gene Tx
FDA+

White House seeks $65B to pre­pare for fu­ture pan­demics in 'Apol­lo'-like ef­fort

Last year
Pharma
Coronavirus

Abrupt FDA ex­its spark con­cern; Un­pack­ing key con­cepts at gene ther­a­py sum­mit; 20 lu­mi­nar­ies who re­shaped R&D; and more

Last year
Weekly

Eli Lil­ly sued by for­mer em­ploy­ees al­leg­ing age dis­crim­i­na­tion, cit­ing hir­ing prac­tices fa­vor­ing in­terns

Last year
Pharma

Pri­vate eq­ui­ty, sov­er­eign wealth fund al­ly on an $8B buy­out aimed at tak­ing rare dis­ease play­er pri­vate

Last year
Deals
First page Previous page 112113114115116117118 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Premium Content
  • Don't Miss
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints Company 2023

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
Endpoints News

Log in to your account

e-mail

password

Endpoints News

request magic link

If you're already an Endpoints subscriber, enter your email below for a magic link that lets you log in quickly without using a password. Please note the magic link is one-time use only and expires after 24 hours.

email

Endpoints News

reset password

We'll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours.

email

Endpoints News

About You

Subscriptions

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 2 PM ET

ENDPOINTS MARKETING RX Tue at 2 PM ET

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET